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Abstract 
Solid organ transplantation (SOT) is increasingly employed worldwide to treat several 
diseases causing both acute and chronic organ failure. Recipients of SOT are at an increased 
risk to develop infections as a consequence of immunosuppressive therapy. Sometimes such 
infections may be acquired by the transplanted organ or by reactivation of a previously 
acquired latent infection. The globalization and the increase of international travel poses a 
risk for exposure to infections such as Chagas disease (CD), leishmaniasis, and malaria 
endemic in tropical and subtropical areas of the world. We have reviewed the literature 
regarding risk factors, clinical presentation, diagnosis, and treatment of CD, leishmaniasis, 
and malaria in the setting of SOT. 
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1. Introduction 
The role of protozoan infections among solid organ transplant (SOT) patients is becoming 
increasingly recognised in both endemic and non-endemic countries, although these infections are 
generally considered rare [1-3]. 
Diagnosis and treatment of infections such as Chagas disease, malaria, and leishmaniasis in the 
setting of SOT is challenging due to multiple factors; to help clinicians to properly manage them, 
several guidelines and recommendations have been published in recent years [4-9]. The use of 
immunosuppressive drugs in transplant patients means that such protozoan infections not only 
can be acquired de-novo (by vectors, transfusion, and the organ transplanted), but can also 
undergo reactivation in those with latent infection due to the induced immunosuppression. 
In the present review, we consider risk factors, clinical presentations, diagnosis, and treatment 
regarding Chagas disease (American trypanosomiasis), leishmaniasis, and malaria in the setting of 
SOT recipients with perspectives of how to screen and follow-up latent infections. 
2. Chagas Disease 
2.1 Introduction 
Chagas disease (CD), or American trypanosomiasis, is a protozoan infection caused by 
Trypanosoma cruzi. Initially described by Carlos Chagas in Brazil at the beginning of 20th century, it 
is widespread and endemic in Mexico as well as Central and South America, where 6 million 
people are infected and 65 million people at risk of contracting the infection [10]. However, the 
huge migration from Latin America to the United States and Europe has driven the emergence of 
CD in these countries with an estimated 68,000-122,000 cases in Europe and 300,000 in the 
United States [11-13]. A recent systematic review and meta-analysis showed a pooled prevalence 
of CD of 4.2% in five European countries, with the highest one (18.1%) found among Bolivian 
immigrants [14]. 
Although CD has been considered a vector-borne disease transmitted to humans by 
hematophagous triatomine bugs (known as “kissing bugs”), the parasite can also be transmitted 
from a mother to her newborn, by transfusion of infected blood, the oral route, and by organ 
transplantation [15]. The first evidence of possible CD transmission by organ transplantation was 
during the early 1980s in Brazil and Chile [16, 17]. In the United States, the first reported case of 
donor-derived CD was in 2001 [18]. Since then, CD has been reported in kidney, liver, heart, and 
lung recipients [19-22].  
CD in SOT recipients can occur through three possible mechanisms: 1) transmission from 
chronically infected donors, 2) reactivation of latent infection in the recipient, or 3) infection 
acquired after transplant due to endemic exposure or possibly from transfusion of infected blood 
product. 
2.2 Risk of Transmission by Infected Donor 
The assessment of the risk of transmission of CD by organ transplantation from seropositive 
donor (D+) to seronegative recipient (R-) is based on a limited number of studies, which are 
generally retrospective and with short follow-up, as seen in Table 1 [21-30]. The average 
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prevalence was 19.3%, ranging from 9.6% for kidney transplant, 17.1% for liver transplant, to 75% 
for heart transplant [24, 27-30]. It is worth noting that in Argentina, the prevalence of T. cruzi 
infection among effective donors doubled (from 2.46% to 4.6%) from 2005 to 2009 [31]. A risk that 
is not negligible was also observed in Brazil, where among 2,822 potential organ donors, 1.3% had 
a positive T. cruzi serology, and the prevalence rate increased from 1.0% in 2010 to 1.6% in 2015 
[32]. 
Table 1 Transmission from Trypanosoma cruzi seropositive donors to seronegative 
recipients (case studies and cohort studies). 
Organ Author/Ref
erence 
Country of 
transplant 
N (%) Prophylaxis Parasit
aemia 
after 
transpl
ant 
Time 
onset, 
median 
(range)  
Outcome 
N° 
deaths/N° 
patients 
(%) 
Kidney 
 
Riarte/23 Argentine 3/16 
(18.7) 
No 3/3 60 (37-
165) days 
1/16 (6.2) 
unrelated 
to CD 
Sousa/24 Brazil 0/9 (0) Yes 0/9 Nihl 0/10 
Huprikar/21 USA 2/16 
(12.5) 
No 2/2 11 weeks 
(5-17) 
3/16 
(18.7) 
Cicora/25 Argentine 0/6 (0) No 0/6 Nihl NR 
Cura/26 Argentine 1/15 (6.7) No NR NR NR 
Liver 
 
Barcan/19 Argentine 1/1 (100) No 1/1 84 days 1/1 (100) 
unrelated 
to CD 
D’Albuquer
que/27 
Brazil 0/6 (0) Yes 0/6 Nihl 2/6 (33.3) 
unrelated 
to CD 
Salvador/28 Spain 0/2 (0) Yes 0/2 Nihl 1/2 (50) 
unrelated 
to CD 
McCormack
/29 
Argentine 2/9 (22.2) Yes 2/9 3 months 2/9 (22.2) 
unrelated 
to CD 
Cura/26 Argentine 5/10 (50) No 2/2 39,5 days NR 
Huprikar/21 USA 2/9 (22.2) No 1/1 10 weeks 3/11 
(27.3) 
Balderramo
/30 
Argentine 0/4 (0) Yes 0/4 Nihl 1/4 (25) 
Heart Huprikar/21 USA 3/4 (75) No 1/1 7 weeks 
(3-9) 
2/4 (50) 
Lung Huprikar/21 USA 1/1 (100) No 1/1 NR 0/1 
Cura/26 Argentine 1/1 (100) No 1/1 73 days 0/1 
Total   21/109 
(19.3) 
5/11 (45.5) 
studies* 
14/48 
(29.2) 
 16/81 
(19.7) 
*References 21 and 26 are counted once; NR, not reported 
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2.3 Risk of Reactivation in Infected Recipients 
Risk of reactivation of T. cruzi infection varies according to the organ transplanted and the 
degree of drug immunosuppression, with the highest risk associated with heart transplantation 
(mean average of 44.9%) and similar risk for kidney (21.7%) and liver (33.3%) transplantation, as 
shown in Table 2 [30, 33-47]. The majority of the studies regarding reactivation came from Brazil 
and are related to patients who undergo heart transplantation, with a prevalence rate ranging 
from 23% to 90% [33-41, 44]. In Brazil, end-stage Chagas cardiomyopathy (CHC) is currently the 
third most common determinant for heart transplants (HTx), but it is also associated with a better 
outcome, with a 12-year survival rate of 46% [33, 47]. A recent study conducted in the United 
States between 2012-2016 showed a rate of reactivation of 61% among patients undergoing HTx 
[45]. In another study from the USA, the rate of reactivation after HTx was 45.5% [46]. 
Table 2 Risk of reactivation of Chagas disease in seropositive transplant recipients. 
Organ Author/Refere
nce 
Country of 
transplant 
N (%) Prophylaxis Median time 
of reactivation 
(range) 
Outcome 
N° 
deaths/N° 
patients 
(%) 
Kidney  Riarte/23 Argentine 5/23 (21.7) No 63 days (35-
730) 
1/23 (4.3) 
Liver Balderramo/30 Argentine 3/9 (33.3) No NR 2/9 (22.2) 
Heart Stolf/34 Brazil 3/4(75) No 81 days (59-
420) 
NR 
Bocchi/35 Brazil 6/12 (50) Yes (only 
first period) 
NR NR 
de 
Carvalho/36 
Brazil 3/10 (30) Yes 17 months (2-
23) 
3/10 (30) 
unrelated 
to CD 
Bocchi/37 Brazil 15/22 (68)   9/22 (40.9) 
at 2 years 
De Souza/38 Brazil 5/18 (23) No NR NR 
Couto/39 Brazil 16/24 (67) NR NR NR 
Fiorelli/40 Brazil 17/59 (29) Yes NR 24/59 
(40.7) 1 
death CDr 
Bacal/41 Brazil 21/39 (53) No NR 5/39 (12.8) 
at 2 years 
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Bestetti/42 Brazil 9/10 (90) No NR 1/10 (10) 
Diez/43 Argentine 5/10 (50) No 75 days (32-
92) for clinical 
manifestation; 
21 days (7-21) 
for kDNA-PCR 
2/10 (20) 
unrelated 
to CD 
Campos/44 Brazil 17/64 (26) No NR NR 
Kransdorf/45 USA 5/11 (45.5) No 23 days 2/11 (18.2) 
Gray/46 USA 19/31 (61) No 3 weeks (<1-89 
weeks) 
1/31 (3.2) 
unrelated 
to CD 
Sub-
total* 
  141/314 
(44.9) 
   
Total   149/346(43.
1) 
  50/224 
(22.3) 
NR, not reported; CD, Chagas disease; CDr, Chagas disease reactivation; KDNA PCR, polymerase chain reaction 
targeted to minicircle variable region; * referred to heart transplant 
The 10-year survival rate of patients with HTx for CHC in the USA study was 57% and did not 
differ from the reported survival rate of patients with idiopathic dilated cardiomyopathy [48]. 
The use of mycophenolate mofetil (MMF) compared to azathioprine has been associated with a 
6-fold higher risk of T. cruzi reactivation in a Brazilian retrospective study of HTx patients [41]. 
Another small study from Brazil reported a 90% reactivation rate among HTx patients treated with 
MMF, although the incidences of other post-transplant morbidities were similar in Chagas and 
non-Chagas disease patients [42]. 
2.4 De Novo Post-Transplant Infection 
De novo acquisition of CD in a seronegative recipient who had received an organ from a 
seronegative donor has been very rarely described but can occur from travel or residence in an 
endemic area as well as through blood transfusions [23, 49]. Riarte et al. reported two kidney 
transplant patients who were infected through the vector route and were diagnosed by 
seroconversion in the absence of any clinical manifestations [23]. 
2.5 Clinical Presentation  
Acute CD has been diagnosed following kidney, heart, liver, and lung transplantation from T. 
cruzi seropositive donors; the clinical picture ranges from asymptomatic parasitaemia detected 
only by polymerase chain reaction (PCR) performed on peripheral blood samples to an acute 
disease presenting with daily high fever or with involvement and dysfunction of the kidney, heart, 
and brain [19, 20, 22, 23, 50, 51]. Besides fever in patients experiencing post-transplant acute 
infection several clinical pictures have been reported: acute chagasic myocarditis, cerebral 
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trypanosomiasis with space-occupying brain lesions or kidney failure [18, 20, 51, 52]. In the above 
cited cases, trypomastigotes were identified in the bloodstream, peritoneal fluid, and 
cerebrospinal fluid, and T. cruzi amastigotes were found in endomyocardial biopsies [20, 51, 52]. 
In an autopsied kidney transplant recipient, disseminated CD was demonstrated with intense T. 
cruzi parasitism involving the heart, liver, spleen, kidney, bladder, and pancreas [51]. The median 
interval from transplantation to diagnosis of acute infection in a US study was 8 weeks, with a 
range of 3-29 weeks [21]. 
Reactivation of CD among seropositive recipients is currently diagnosed by detection of blood 
parasitaemia by polymerase chain reaction (PCR) or by endomyocardial biopsy (among HTx 
patients) which allows early preemptive therapy and improved survival [36, 43]. The Chagas 
reactivation rate in patients who underwent HTx is reported on average to be 41%, ranging from 
23% to 90%, depending on the study [32, 34, 36-46]. Multiple episodes of reactivation (up to eight) 
have been described among patients who underwent heart transplantation [40]. A parasitological 
response is generally rapidly achieved as documented by the absence of parasites by Strout 
analysis after one week of treatment, although using more sensitive methods such as kDNA PCR a 
negative results is observed between 1 and 2 weeks after treatment [26, 43]. Clinical 
manifestations include febrile illness, new onset of painful wine-colored nodules (metastatic 
chagomas) which can ulcerate, erythematous plaque or panniculitis, acute myocarditis, or tumor-
like brain lesions mimicking toxoplasmosis or neoplastic processes [53-59]. Myocarditis and 
meningoencephalitis can run an aggressive course, rapidly leading to the death of the patients [58-
60]. Nevertheless, the outcome and survival rate of SOT recipients who develop acute CD or 
reactivation of the disease, especially among heart transplant recipients monitored and treated 
promptly, is similar to patients not affected by CD and in some instances even better [23, 30, 33, 
36, 37, 46]. Among liver transplant recipients in Argentina, the median stay in intensive care, 
median hospital stay, rate of acute graft rejection, rate of infection, and rate of graft survival was 
similar in patients at risk of CD compared to the controls, with no deaths attributable to acute CD 
[30]. Mortality related to CD reactivation among HTx recipients has been reported in 0.3% to 0.7% 
of patients in Brazil and in 0% of patients in a recent study in the USA [33, 40, 46]. 
2.6 Diagnosis 
Diagnosis of chronic T. cruzi infection is achieved by two positive serology methods employing 
different antigens as recommended by the World Health Organization (WHO). A third test, such as 
immunoblotting with trypomastigote excreted-secreted antigen (TESA), is indicated when serology 
is inconclusive (one positive and one negative test) and to rule out cross-reactions (with 
Leishmania). PCR shows a low sensitivity due to low parasitaemia during chronic infection and 
should not be used as a screening test [61]. On the contrary, PCR for T. cruzi performed on blood is 
currently considered the gold standard for post-transplant monitoring and early diagnosis of acute 
infection or reactivation [26, 30, 43]. Quantitative real-time PCR monitoring during the first 6 to 24 
months post-transplant is actually recommended and employed in the centers transplanting the 
organs of Chagas disease patients [1, 5, 9, 31, 45]. Direct parasitological examination (Strout 
method or blood smear) on peripheral blood, cerebrospinal fluid, or pericardial fluid as well as 
histopathology are less sensitive, although usually employed [20, 51, 52]. Blood culture and 
xenodiagnosis are also less sensitive and time-consuming methods. Interestingly, serological 
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response in acute post-transplant CD can be completely abrogated or can be delayed, and in 
patients with reactivated disease, a decrease of IgG1 and IgG3 titres has been shown [19, 23]. 
2.7 Indication, Screening, and Management of Chagas Disease in SOT 
Recommendations regarding different aspects of CD and SOT (i.e., who should be transplanted, 
what organs from seropositive T. cruzi donors should be used or discarded, how to screen patients 
before and after transplantation, how to treat CD, etc.) have been released from Argentine, Brazil, 
Spain, the USA, and from a working group from Latin America, as shown in Table 3 [5, 6, 9, 31, 62]. 
Table 3 Chagas disease recommendations for Solid Organ Transplant recipients. 
Country, 
year, 
reference 
Argentine, 
2010, [31] 
USA, 2011, 
[9] 
Spain, 2011, [6] Latin America, 
2018, [5] 
Brazil,2016, 
[62] 
Pre-
transplan
t 
screening 
of 
putative 
recipients 
* All native 
from Latin-
American  
* born to Latin 
American 
mothers  
*recipients of 
unscreened 
blood or blood 
products  
* resident or 
traveller to 
high risk areas 
for > 6 months 
* Universal 
testing for 
those born 
in endemic 
areas 
*Native population 
from endemic areas 
* Population who 
have received a 
blood transfusion in 
endemic countries 
* Offspring of 
mothers who are 
native from an 
endemic country 
and have a positive 
or unknown 
serology for Chagas 
* Population who 
have lived in an 
endemic area fro 
more than 1 month 
* Systematic 
screening is 
required for all 
recipients at 
risk for T. cruzi 
infection 
before 
transplant 
* Screening 
mandatory  
Pre-
transplan
t 
screening 
of 
putative 
donors 
Same as for 
putative 
recipients 
Targeted 
screening 
for donors 
born in 
Latin 
America 
Same as for 
putative recipients 
* Systematic 
screening is 
required for all 
donors at risk 
for T. cruzi 
infection 
before 
transplant 
* Screening 
mandatory for 
all donations 
(use the same 
algorithm for 
blood 
donations) 
Which 
tests 
should be 
used for 
screening 
Chagas 
disease 
Two 
serological 
tests using 
different 
methodologie
s 
Ortho EIA 
and 
Abbott 
Prism 
Chagas 
tests 
Rapid serologic test 
with high 
sensitivity; 
confirmation by 2 
specific serological 
techniques 
required 
Two different 
serologic tests 
Two different 
serologic tests 
Acceptan Infected Transplant The heart and the The decision to Law restriction 
OBM Transplantation 2019; 3(1), doi:10.21926/obm.transplant.1901039 
 
Page 8/23 
ce of 
organs 
from 
donor 
with CD 
deceased 
donors are 
unacceptable 
for heart 
transplantatio
n. The 
allocation of 
other organs, 
with 
appropriate 
informed 
consent, could 
be acceptable 
for infected 
recipients; for 
uninfected 
kidney 
recipients and, 
eventually, for 
uninfected 
lung and liver 
recipients in 
emergency 
situations 
centers 
can 
consider 
transplanti
ng kidneys 
and livers 
from T. 
cruzi 
infected 
donors. 
Rejection 
of hearts 
from T. 
cruzi-
infected 
donors. 
Lung, 
pancreas 
and 
intestine 
can be 
considered 
with 
caution. All 
patients 
should 
provide 
appropriat
e informed 
consent 
concerning 
risk and 
benefits 
intestines should 
be excluded for 
transplantation. For 
the remaining 
organs, 
transplantation will 
be possible subject 
to the informed 
consent of the 
recipient (without 
other options and 
for urgency cases) 
accept an 
organ from an 
infected donor 
is a balance 
between 
urgency of 
need for the 
organ and the 
acceptance of 
the risk of 
possible 
infection in the 
recipient, both 
by the medical 
team and the 
recipient 
through 
informed 
consent, along 
with the ability 
to diagnose 
and treat 
infection if it 
occurs 
on the use of 
organs from CD 
patients. The 
team will 
decide whether 
the organ is 
acceptable for 
use or not 
regarding 
kidney, 
kidney/pancrea
s, liver and lung 
donations 
Criteria 
for 
microbiol
ogic 
diagnosis 
of 
reactivati
on 
Not reported Not 
reported 
* Positive Strout 
method 
* Positive PCR in 
patients with 
previous negative 
PCR 
* Direct 
detection of T. 
cruzi in blood, 
fluids and 
tissues 
* High levels of 
quantitative 
PCR 
* Direct 
microscopic 
detection of T. 
cruzi in blood, 
fluids and 
tissues 
 
Post-
transplan
t 
monitori
ng of 
patients 
receiving 
Monitoring 
weekly or 
every 2 weeks 
for the first 6 
months, 
monthly 
thereafter, 
Monitorin
g with T. 
cruzi PCR 
and 
microscop
y of blood 
specimens 
Parasitologic 
studies 
(quantitative PCR, 
Strout method, 
direct parasitologic 
test according to 
the possibilities of 
Monitoring 
weekly during 
the first 2 
months, every 
2 weeks 
through 
months 3 to 6, 
Sequential 
parasitologic 
monitoring in 
the peripheral 
blood, every 
week for up to 
60 days and 
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an organ 
from an 
infected 
donor 
and weekly for 
2 months after 
intensification 
of 
immunosuppr
ession 
weekly for 
the first 
two 
months, 
every 2 
weeks 
during the 
third 
month, 
then 
monthly 
until at 
least 6 
months 
post-
transplant
ation 
the laboratory. 
Weekly for 2 
months, bimonthly 
between the 
second and sixth 
months post-
transplant, annually 
thereafter 
and annually 
thereafter or 
at any time 
after an 
intensification 
of 
immunosuppr
ession 
indirect 
parasitologic 
and serology 
examination on 
days 30 and 60 
after 
transplantation. 
Thereafter , 
clinical, 
serologic and 
parasitologic 
(direct/indirect/
PCR)examinatio
ns should be 
performed 
every two 
months for up 
to one year of 
follow-up; then 
every 6 months 
for as long as 
immunosuppres
sion persists 
Prophyla
xis for 
recipients 
of 
infected 
organs 
The risk of 
toxicity among 
patients with 
end-stage 
renal disease 
and liver 
insufficiency, 
seems to 
outweight its 
potential 
benefit 
Prophylaxi
s not 
recommen
ded 
Consider use of 
post-transplant 
prophylaxis or early 
treatment of 
reactivation 
Monitoring 
preferred over 
the use of 
prophylaxis 
Monitoring 
preferred over 
the use of 
prophylaxis. 
Prophylaxis 
indicated if the 
sequence 
monitoring is 
not indicated 
 
Chagas cardiomyopathy is not an absolute contraindication to heart transplantation, although 
some centers have adopted strict clinical and laboratory monitoring protocol to diagnose early, 
asymptomatic reactivation and early institution of treatment [45]. Similarly, patients with chronic 
indeterminate CD are considered suitable candidates for other solid organ transplants. Spanish 
guidelines specifically contraindicate any type of transplant for patients with advanced 
megaesophagus or megacolon [6]. Serologic screening is recommended both for candidate donor 
and recipients who share epidemiologic risk factors for CD, such as those born in Latin America, 
those born in non-endemic countries by Latin American mothers, recipients of blood transfusions 
in endemic countries, and those who have resided or travelled in Latin America [5, 6, 9, 31]. 
All guidelines indicate the use of two serological techniques for confirming the diagnosis of T. 
cruzi infection, whereas US guidelines specifically recommend the use of an FDA-cleared test 
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(Ortho EIA and Abbott Prism Chagas test) with additional testing by the Center for Disease Control 
(CDC) if a donor is found positive [9]. The use of organs from CD-infected donors is a matter of 
debate with absolute and relative contraindications; all guidelines absolutely contraindicate the 
use of the heart from a positive donor in positive or negative recipients [5, 6, 9, 31]. This is the 
consequence of the high rate of CD transmission with heart transplantation observed in a series of 
patients in which the CD diagnosis was discovered “a posteriori” *21+. This statement is in 
agreement with a recent autopsy study demonstrating the persistence of T. cruzi in 57.1% of heart 
samples [63]. 
In the same study, no samples from the lung, liver, kidney, pancreas, esophagus, or 
gastrointestinal tract were found to have the parasite as detected by histology, 
immunohistochemistry, or PCR. However, Spanish guidelines also recommend against the use of 
small bowel from infected donors [6]. In general, all guidelines indicate that liver and kidney 
transplants from positive donors can be made in cases of urgency, having obtained an appropriate 
informed consent concerning risk and benefits from the patient [6, 9, 31]. 
All guidelines advise to monitor post-transplant patients with laboratory tests (quantitative PCR, 
Strout method) that are able to identify parasites in the bloodstream responsible for de novo 
acute infection or reactivation among infected recipients [5, 6, 9, 31]. Indications about timing are 
similar among the recommendations, with close monitoring during the first 6 months after 
transplantation and when an intensification of immunosuppressive drug regimen is needed (Table 
3). Heart transplant patients are recommended closer and more prolonged parasitologic 
monitoring, including evaluation of endomyocardial biopsies [5, 6, 9, 31, 64]. 
As far prophylaxis, among recipients of infected organs and in patients with chronic CD, 
guidelines favour an approach based on careful monitoring over the use of prophylactic treatment 
because of lack of evidence and the potential of drug toxicity [5, 6, 9].  
In regard to immunosuppressive drug regimens, mycophenolate mofetil (MMF) should be 
avoided, especially in heart transplant recipients, and replaced by azathioprine or cyclosporine; 
when possible, antithymocyte globulin should also be avoided for rejection prevention [5, 6]. 
Basiliximab and daclizumab have been suggested as possible alternatives to MMF during the 
induction phase [6]. Moreover, based on an in vitro study showing activity against T. cruzi growth, 
rapamycin is indicated as another possible alternative to the use of MMF [5, 6]. Finally, it is 
recommended to maintain the immunosuppression at the lowest possible level, and a single 
retrospective study conducted in heart transplant recipients found patients receiving lower doses 
of cyclosporine (3-5 mg/kg versus 5-10 mg/kg) had significantly lower reactivation rates than those 
receiving higher doses of cyclosporine [5, 6, 60]. 
Benznidazole (5 mg/kg/day) is generally recommended as a first line drug for treatment of 
acute infection and reactivation for 30 or 60 days [5, 6, 31]. The choice of benznidazole is dictated 
by its better tolerability, although studies evaluating drug interactions with immunosuppressive 
drugs are lacking. In patients with renal or hepatic failure, no dose adjustment is needed. 
Nifurtimox (8-10 mg/kg/day) is considered a second choice that requires a more prolonged 
administration (90 days). Both drugs are metabolised by cytochrome P450, thus, with possible 
increase of cyclosporine, tacrolimus, sirolimus, and everolimus blood levels [5]. A frequent 
monitoring of blood cell count is needed for both drugs because of potential myelosuppression 
[5,6]. Skin rash, peripheral neuropathy, insomnia, and gastrointestinal intolerance are other 
possible adverse effects associated with anti-trypanosomal drugs [5, 6]. 
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3. Leishmaniasis  
3.1 Introduction  
Leishmaniasis refers to a group of vector-borne diseases caused by more than 20 Leishmania 
species belonging to the family Trypanosomatidae [65-67]. The natural reservoir of the parasite 
can be animal (zoonotic leishmaniasis) or human (anthroponotic leishmaniasis). The disease can 
present in four main forms: cutaneous leishmaniasis (CL), mucocutaneous leishmaniasis (MCL), 
visceral leishmaniasis (VL), and post-kala-azar dermal leishmaniasis (PKDL). In 2015, according to 
the WHO, 87 and 75 countries were considered endemic for CL and VL, respectively, with almost 
200,000 new cases of CL and 25,000 new cases of VL [65]. 
SOT recipients can develop de novo Leishmania infection through vector transmission, 
reactivation of a latent infection, or acquire the infection by donated organ or blood transfusion, 
although this occurs less frequently [68, 69]. 
VL is the picture observed more frequently among SOT recipients whereas CL and MCL are only 
occasionally reported [68, 70-72]. Leishmaniasis is described predominantly among kidney 
transplant recipients in comparison with other SOT recipients, but it is presently unknown if this is 
due to an increased risk related to renal failure or dialysis or due to the fact that kidney 
transplants comprise the great majority of SOTs [65, 68, 73-75].  
3.2 Risk Factors 
Only few studies have evaluated seroprevalence of Leishmania infection among candidates for 
organ transplantation or recipients of SOT [74, 76-78]. A study from northeastern Brazil conducted 
among 310 haemodialysed patients showed a 22.3% reactivity to Leishmania by indirect 
fluorescence antibody test [74]. Another study from Brazil evaluating 50 liver recipients and 17 
liver donors found a 1.5% seroprevalence, but when polymerase chain reaction (PCR) was applied, 
23.5% of donors and 8% of recipients resulted positive for PCR-specific Leishmania infantum either 
in blood, liver, or spleen samples [76]. In the USA, five out 48 (10.6%) Hispanic transplant 
candidates had positive Leishmania antibody titres [77]. Finally, a study from southern Spain found 
a 4.8% prevalence of positive Leishmania antibodies from 625 asymptomatic renal transplant 
recipients [78]. A multicenter case-controlled study performed in Brazil and Spain found a 5.7-fold 
higher incidence of VL in the former country that has been explained by the higher incidence of VL 
in Brazil (1.8 cases per 100,000 inhabitants) in comparison with Spain (0.4 cases per 100,000 
inhabitants) and by an earlier onset of the disease as a consequence of reactivation [79]. In the 
above cited study, high-dose prednisone in the preceding 6 months was the only independent risk 
factor significantly associated with development of VL (OR 2.5) [79].  
Interestingly, a study conducted in Madrid during an outbreak of leishmaniasis found an annual 
risk of developing VL among SOT recipients 136 times higher compared to immunocompetent 
subjects living in the same area [80]. Three risk factors emerged as associated with the diagnosis 
of VL: 1) living in close proximity to the area affected by the outbreak (relative risk 11.74%), 
explained by a higher chance to be bitten by the infected phlebotomous; 2) receiving a SOT during 
the outbreak; and 3) being black from sub-Saharan Africa, with a relative risk of 6.40% [80]. The 
role of ethnicity and its possible association with VL needs to be explored in future studies, as 
black people emerged as the most affected in another study from Brazil [81]. 
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3.3 Clinical Presentation 
VL is by far the most frequently encountered clinical presentation of leishmaniasis among SOT 
recipients described in kidney, liver, heart, lung, and pancreas transplantation [7, 68, 79-81]. Fever 
is the most common symptom of VL, but in the study by Clemente et al., 14% of patients were 
afebrile [68, 79]. Visceromegaly (either hepatomegaly or splenomegaly) has been variably 
reported in the literature but is generally high (75-81%), although only one-third of patients 
present with the classic triad of fever, visceromegaly, and pancytopenia [68, 79, 81]. The median 
time to diagnosis of VL after transplantation ranges from 11 months to 28 months, although in one 
study, one-third of patients were diagnosed within the first 6 months following transplantation [79, 
81]. Active bleeding from the digestive tract was observed in 23% of patients and can be the mode 
of onset of the disease [81, 85]. Septic shock has been reported in 8% of patients in one study [79]. 
Concurrent cutaneous and visceral leishmaniasis has been observed among kidney and liver 
transplant recipients and both typical and atypical presentation of CL are reported in the literature 
[86-90]. Mucosal leishmaniasis localised on the tongue, lip, labial commissure, and nose has been 
described among SOT patients almost exclusively in the Mediterranean basin where the species 
responsible is L. infantum [68, 91-95]. Relapse of VL was reported in 26% to 28% of SOT patients 
and in one of these studies, more frequently among patients not receiving prophylaxis (34.8%) 
than those receiving prophylaxis (8.3%), with a p value of 0.19 [79, 81]. Relapse of VL has been 
reported to occur among kidney transplant recipients in a period ranging from 1 month to 5 years 
after the initial diagnosis [95]. Multiple episodes of relapse, as observed in HIV-positive patients, 
can be diagnosed also among SOT recipients, although for those living in endemic areas it is 
difficult to rule out reactivation from reinfection [95]. 
3.4 Diagnosis 
A direct diagnosis of leishmaniasis (VL, CL, MCL) requires the demonstration of protozoa in 
biopsy samples from bone marrow or the spleen (VL) or from skin ulcer or mucosal lesions. This 
task can be achieved by microscopy, culture, or molecular diagnosis. In the study by Clemente et 
al., the sensitivity of bone marrow microscopy for the diagnosis of VL was 80.6%, better than the 
75% achieved by polymerase chain reaction and the 56% achieved by culture [79]. However, in the 
same study, combining the three methods yielded a sensitivity of 89% [79]. Polymerase chain 
reaction (PCR) is considered the best available method for the diagnosis of VL, combining high 
sensitivity and specificity, rapid species identification, and the advantage of using peripheral blood 
samples (rather than bone marrow) with identical sensitivity and specificity [96]. However, the 
utilization of PCR in SOT is limited to few reported cases [79, 95, 97, 100]. Moreover, the problem 
of asymptomatic patients with positive PCR results needs to be considered because a threshold 
value capable of distinguishing this condition (asymptomatic parasitaemia) from the disease is 
presently unknown. It should be highlighted that in a recent case report of VL in a lung transplant 
recipient using real-time PCR which targets the kinetoplastic DNA, the authors were able to 
retrospectively detect the DNA of the parasite months before the diagnosis, suggesting the 
possibility to adopt a preemptive approach [97]. Leishmania serology has been reported to be 
positive in 76% of SOT patients with VL, but it is unable to distinguish between prior exposure and 
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active disease; additionally, in areas where Chagas disease coexists, cross-reactivity can be a 
problem because both parasites share antigens [7, 98]. 
3.5 Screening and Management of Leishmaniasis 
Since there is not a clear demonstration of the utility of screening either among candidate 
organ transplant recipients or organ donors, available guidelines do not recommend this practice 
[7, 99, 100]. It is generally recommended that transplant recipients visiting endemic countries use 
insect repellent and avoid outdoor activities during the hours when sand flies are more active [7]. 
Liposomal amphotericin B (L-AMB) is considered the drug of choice for the treatment of 
leishmaniasis in SOT with a cumulative dose of 40 mg/kg administered over 10 infusions (days 1-5 
followed by one week administration for 5 times) [100]. The liposomal formulation of 
amphotericin B is generally well tolerated and is preferred over amphotericin B deoxycholate 
among SOT recipients [79, 81]. In a review of the literature, the initial cure rate of VL among 
transplant recipients has been documented as 84% [68]. A Brazilian study conducted among 
kidney transplant recipients reported an 80% VL remission and return to dialysis in 33% of patients 
achieving VL remission [81]. Finally, in a Spanish–Brazilian study involving kidney, liver, heart, and 
lung transplant recipients, the cure rate at the one month follow-up was reported to be 94.2% [79]. 
Experience with miltefosine (the only available oral therapy for VL) in the setting of SOT is 
limited to 6 patients in whom the drug was used as salvage treatment after first-line therapy with 
L-AMB [101]. Patients were treated with 2.5 mg/kg/day of miltefosine for 28 days but 50% 
relapsed after an initial clinical improvement. As commonly used in HIV-infected patients, a 
secondary prophylaxis seems to also be warranted among SOT recipients, although the interval 
and means of administration are presently unknown [7, 79]. As far as the treatment of CL in SOT 
recipients, it is recommended to use the same systemic treatment (i.e. L-AMB) as for VL [7].  
4. Malaria 
4.1 Introduction 
Malaria is the most common human protozoan disease worldwide caused by six different 
species of Plasmodium: Plasmodium falciparum, P. vivax, P. ovale wallikeri, P. ovale curtisi, P. 
malariae, and P. knowlesi, the latter being a zoonotic parasite emerging in East Asia [102]. The 
disease is usually transmitted by the bite of infected Anopheles mosquitoes, but transmission by 
blood (via transfusion or sharing of contaminated needles), by mother to child, or following organ 
transplantation is also possible [103-106]. Post-transplant malaria may be the consequence of a 
donor-derived infection, transmission by blood transfusion, recrudescence, or relapse of a 
previous infection in the transplant recipient [107-109].  
4.2 Donor Deferral and Screening 
There are no uniform recommendations about deferral of candidate donors who have resided 
or travelled in endemic areas for malaria. In general, most recommendations refer to adopted 
policies for exclusion of blood donors [110]. The European Society of Clinical Microbiology and 
Infectious Diseases (ESCMID) recommendations indicate screening with nucleic acid tests (NATs) in 
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all donors and recipients who have resided or travelled to areas of malaria endemicity in the 3 
preceding years *111+. If the donor’s death is secondary to malaria, organs should be rejected 
[111]. Brazilian guidelines and the recently published guidelines from Latin America recommend 
routine screening for donors coming from endemic regions, based on annual parasite incidence 
(API), and excluding those with a diagnosis of malaria in the previous 12 months, with fever in the 
previous 30 days, or having returned from a city with a high API in the previous 30 days [2, 8]. 
Candidate donors who had a history of P. malariae are permanently deferred from donation 
because this parasite probably persists for life, posing a risk even decades after a previous episode 
of apparently cured malaria, as observed in cases of transfusion-transmitted malaria [8, 103]. 
Moreover, potential donors with a diagnosis of active infection should be deferred from organ 
donation until the malaria is diagnosed and treated. All guidelines recommend the use of 
molecular screening with NATs which are able to detect low parasitaemia, a condition which can 
be missed by thick blood smears and rapid antigen tests that are considered insensitive [2, 8, 111]. 
Serology testing can be considered as a marker of previous exposure in the case of unclear donor 
travel history.  
Even with the use of the most sensitive diagnostic test on blood, liver transplantation has been 
associated with the transmission of P. vivax due to the persistence of hepatic hypnozoites, which 
is also possible for P. ovale [112, 113]. Several cases of multi-organ transmission of malaria from a 
single donor have been described [107, 114, 115]. 
4.3 Post-Transplant Management 
Malaria also carries a possible risk of recrudescence or reactivation among recipients with 
asymptomatic infection following immunosuppression [116]. For this reason, it has been 
suggested to prospectively monitor high risk patients (i.e., those coming from malaria-endemic 
areas) with PCR for a period of two months [117].  
4.4 Clinical Presentation 
Post-transplant malaria presents with high fever and chills that do not respond to empirical 
antibiotic therapy [107, 114, 115, 118-121]; thrombocytopenia and anemia are commonly 
observed as in the case of vector-borne malaria [114, 115, 118-121]. Mental impairment, coma, or 
acute renal failure may be observed as complications of P. falciparum malaria when the diagnosis 
is delayed [115, 118, 119]. Patients with a diagnosis of malaria after a liver transplant can display 
liver function deterioration with important increases of transaminases and bilirubin [107, 112, 
115]. Malaria diagnosis in cases occurring through infected grafts is entertained after a median of 
29.5 days [8]. Death of the patient was reported in 12% of cases recently reviewed, with the worst 
outcome among liver and heart transplant patients, although the overall low number of malaria 
cases prevent any definite conclusion [8]. 
4.5 Diagnosis 
In all the reported cases of post-transplant malaria, the correct diagnosis was always achieved 
by conventional thick and thin smears of peripheral blood [8, 107, 112-115, 118-121]. Few cases of 
mixed infections caused by P. falciparum and P. vivax as well as by P. malariae and P. ovale were 
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reported in the literature [114, 121]. To the best of our knowledge, a very sensitive quantitative 
PCR for malaria has been used only in a single case of an allogenic haematopoietic stem cell 
transplant patient; it showed a long-term persistence of a positive PCR result (> 30 days) after 
therapy-induced resolution of symptoms and parasite disappearance detected by microscopy 
[109]. 
4.6 Treatment 
Patients were treated according to the species of Plasmodium identified and the severity of the 
malaria picture observed [107-109, 112-115, 119-121]. There is an anecdotal report of two 
patients who underwent a pre-emptive treatment for malaria after the recognition of the disease 
in a recipient from the same organ donor [122]. Artesunate, the drug of choice for severe malaria, 
has been employed in a single case of malaria in a heart transplant patient [115].  
The recommendations for treatment of malaria in SOT recipients are essentially the same as for 
the population of non-transplant patients [8]. 
5. Conclusion 
In conclusion, although rarely observed, CD, leishmaniasis, and malaria pose a risk that is not 
negligible among SOT recipients, especially in the present era of globalisation. The awareness of 
this risk in recent years has led to the introduction of molecular tests in the clinical practice to 
screen both donors and recipients (especially for CD), and to promulgate recommendations and 
guidelines. The risk of reactivation is particularly important for CD, requiring PCR monitoring of the 
blood in order to make an early diagnosis and preemptive therapy. High quality studies are 
needed to accurately identify risk factors for CD reactivation. 
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